Phase Two: The Pharmaceutical Industry Responds to AIDS Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Merck R&D budget (1990s): Approximately $1 billion annually (Exhibit 1).
• Cost to bring a new drug to market: Estimated at $231 million in 1990 dollars (Exhibit 2).
• Pricing of Crixivan: Set at $12,000 per patient per year at launch (Paragraph 14).
• Market size: Estimated 1 million HIV-infected individuals in the US; 20 million globally (Paragraph 3).

Operational Facts

• Drug Development Pipeline: Protease inhibitors represented a high-risk, high-reward bet on viral replication inhibition (Paragraph 8).
• Manufacturing: Crixivan required complex, multi-step chemical synthesis; production capacity was a primary bottleneck (Paragraph 18).
• Clinical Trials: Accelerated FDA approval process (Subpart H) utilized for the first time for HIV therapeutics (Paragraph 12).

Stakeholder Positions

• Roy Vagelos (CEO, Merck): Committed to prioritizing HIV research despite initial skepticism from the board regarding market size (Paragraph 5).
• HIV Activists (ACT UP): Demanded lower drug prices and faster access to clinical trials; pressured both FDA and pharmaceutical firms (Paragraph 9).
• FDA: Balanced the need for rapid access against the requirement for rigorous safety data (Paragraph 11).

Information Gaps

• Post-1996 competition: The case lacks long-term data on the entry of generic manufacturers and the subsequent impact on pricing tiers in developing markets.
• Internal Cost Structure: Specific COGS for Crixivan is not provided, making margin analysis speculative.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should Merck price and distribute Crixivan to balance the tension between recouping massive R&D investment and fulfilling its public health responsibilities in the face of intense activist pressure?

Structural Analysis

• Value Chain: The pharmaceutical development process is front-loaded with risk. R&D represents 80% of the cost structure, while production is relatively inexpensive once the molecule is stabilized.
• Porter Five Forces: Supplier power is low; buyer (patient/government) power is high due to intense political mobilization. Threat of substitutes is high as new protease inhibitors are reaching the market.

Strategic Options

• Option 1: Tiered Pricing Model. Implement high prices in developed markets and deeply discounted pricing in developing nations. Trade-off: High complexity in preventing arbitrage; risks devaluing the brand in high-margin markets.
• Option 2: Voluntary Licensing. License the Crixivan patent to generic manufacturers in exchange for royalties. Trade-off: Loss of direct control over quality; immediate erosion of monopoly pricing power.
• Option 3: Strict Price Maintenance. Maintain a uniform global price based on the value of life-years saved. Trade-off: Certain public relations disaster; potential for government-mandated price controls.

Preliminary Recommendation

Adopt Option 1. Tiered pricing satisfies the need for capital recovery in the US/EU while providing a defensible ethical stance in resource-poor regions.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

• Month 1-3: Establish a Global Access Department to manage tiered pricing contracts.
• Month 4-6: Secure legal frameworks to prevent reverse-importation of discounted drugs into high-price markets.
• Month 7-12: Launch regional distribution partnerships in Sub-Saharan Africa and Southeast Asia.

Key Constraints

• Supply Chain Transparency: Tracking the movement of goods to prevent diversion is essential. Failure leads to brand damage.
• Local Healthcare Infrastructure: The drug requires consistent refrigeration and monitoring. Without this, the drug is ineffective, leading to drug-resistant HIV strains.

Risk-Adjusted Implementation

Assume 15% of discounted inventory will be diverted to black markets. Build this into the cost model as an acceptable tax for market entry and public goodwill.

4. Executive Review and BLUF (Executive Critic)

BLUF

Merck must move beyond a simple pricing strategy. The challenge is not merely the price of the pill; it is the delivery of the therapy. If the drug is provided without the infrastructure for patient monitoring, the outcome will be widespread treatment failure, drug resistance, and a subsequent public relations crisis. The company should prioritize a partnership model with the WHO and regional health ministries, focusing on authorized distribution chains rather than just price points. This mitigates the risk of diversion and ensures treatment efficacy. The current analysis correctly identifies tiered pricing as a necessity, but it underestimates the operational requirement of medical oversight. Without a commitment to regional infrastructure support, the tiered pricing model will fail both the patient and the shareholder.

Dangerous Assumption

The assumption that the drug is a standalone product. It is a system-dependent therapy.

Unaddressed Risks

• Drug Resistance: Improper use due to lack of medical oversight will create resistant strains, effectively killing the market for the drug.
• Legislative Retaliation: Ignoring the activist pressure will lead to compulsory licensing in key markets, which is a total loss of property rights.

Unconsidered Alternative

Direct investment in localized clinical training programs to ensure the drug is administered correctly, creating a barrier to entry for competitors who only provide the product.

Verdict: APPROVED FOR LEADERSHIP REVIEW.